Clinical Trial Update: Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs [Phase 4]

View source ↗

Summary

A phase 4 clinical trial evaluating a treat-to-target strategy in ankylosing spondylitis using etanercept and conventional synthetic DMARDs.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Spondyloarthritis

Drugs mentioned

• Etanercept (etanercept)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Ankylosing Spondylitis, Spondyloarthritis | Phase 4 | Status: UNKNOWN